YAP/TAZ activation shows varied patterns between distinct cancer types and unique tumors, which makes it difficult to create broadly applicable inhibitors because precise patient classification is required to prevent ineffective or dangerous results (Zhu et al., 2024[189]). The gene discussed is YAP1; the disease is cancer.